Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register

OBJECTIVES: To assess whether age, at the beginning of biologic treatment, is associated with the time a first adverse event (AE) appears in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA). METHODS: All patients in the BIOBADASER registry diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales: Vela, Paloma, Sanchez-Piedra, Carlos, Perez-Garcia, Carolina, Castro-Villegas, María C., Freire, Mercedes, Mateo, Lourdes, Díaz-Torné, Cesar, Bohorquez, Cristina, Blanco-Madrigal, Juan M., Ros-Vilamajo, Inmaculada, Gómez, Silvia, Caño, Rocio, Sánchez-Alonso, Fernando, Díaz-González, Federico, Gómez-Reino, Juan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296933/
https://www.ncbi.nlm.nih.gov/pubmed/32539800
http://dx.doi.org/10.1186/s13075-020-02231-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296933/
https://www.ncbi.nlm.nih.gov/pubmed/32539800
http://dx.doi.org/10.1186/s13075-020-02231-x

Ejemplares similares